- Home
- About
- Section Advisors
- Meet Our Field Medical Affairs Team
- Speakers Bureau
- Supporting Organizations
- Contact Us
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Infographics
- Learning Tracks
- Podcasts
- Shareable/Downloadable Content
- Videos
- PsychUSim
- PsychU Roleplay
- Frameworks In Health & Quality Resources
- Mental Health System Guidebooks
- Psychiatric Scales
- Psychopharmacology
- Supporting Organizations
Long-Acting Injectable Antipsychotics & The Evolving Healthcare Landscape Post-COVID-19 Pandemic For Patients With Schizophrenia & Bipolar I Disorder
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Long-Acting Injectable Antipsychotics & The Evolving Healthcare Landscape Post-COVID-19 Pandemic For Patients With Schizophrenia & Bipolar I Disorder
Schizophrenia and Bipolar Disorder have a significant burden that is expected to have escalated due to COVID-19. People with serious mental illness are at increased risk of COVID-19 and have higher rates of hospitalization, morbidity, and mortality. Drs. Correll and Chen will discuss how the pandemic has affected patients with schizophrenia and bipolar disorder, including access to long-acting injectable antipsychotics.
Moderator:
Gina Lau, PharmD
Regional Medical Lead, Otsuka Pharmaceutical Development & Commercialization, Inc.Featuring
-
Christoph Correll, MD
Chair of the Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany. Professor of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, USA.
-
Maxine Chen , PhD
Director, U.S. Medical Affairs, Otsuka Pharmaceutical Development & Commercialization
-
Gina Lau, PharmD (OPDC)
Regional Medical Lead
Christoph Correll, MD is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. Maxine Chen, PhD and Gina Lau, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc.
Related Events
-
The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities
October 10 12:00 pm to 1:00 pm
Registration
Related Resources
-
Understanding Digital Therapeutics
Infographic April 22, 2024Digital therapeutics (DTx) deliver software-based interventions to patients to treat, manage, or prevent a disease or condition.
-
Understanding MDD Treatments With Neuroplastic Effects
Infographic April 22, 2024Researchers are exploring whether it is possible to leverage neuroplasticity to develop treatments for depression.
-
Understanding Neuroplasticity In Depression
Infographic April 22, 2024The brain is constantly changing! The ability of the brain to create, reorganize, or eliminate connections between neurons (synapses) and change how its circuits are wired is called neuroplasticity.
Join today for instant access to all PsychU content, events, and more!
Membership is free!
"*" indicates required fields
Join PsychU Today to receive a wide array of tools and benefits
- Join our multidisciplinary community that is improving mental health care… together
- Quickly learn more about the topics you're interested in
- Access an award-winning library of on-demand mental health resources
- Gain key insights from industry expert & thought leaders
Stay Connected: